X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with Panacea Biotech - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA PANACEA BIOTECH SHASUN PHARMA/
PANACEA BIOTECH
 
P/E (TTM) x 123.9 155.1 79.9% View Chart
P/BV x 8.5 3.4 247.7% View Chart
Dividend Yield % 0.2 0.0 -  

Financials

 SHASUN PHARMA   PANACEA BIOTECH
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
PANACEA BIOTECH
Mar-14
SHASUN PHARMA/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs94149 63.3%   
Low Rs4682 55.4%   
Sales per share (Unadj.) Rs214.284.1 254.5%  
Earnings per share (Unadj.) Rs5.3-18.3 -29.1%  
Cash flow per share (Unadj.) Rs15.8-6.7 -236.2%  
Dividends per share (Unadj.) Rs1.000-  
Dividend yield (eoy) %1.40-  
Book value per share (Unadj.) Rs53.383.7 63.7%  
Shares outstanding (eoy) m56.6261.25 92.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.31.4 23.8%   
Avg P/E ratio x13.1-6.3 -207.6%  
P/CF ratio (eoy) x4.4-17.2 -25.6%  
Price / Book Value ratio x1.31.4 95.0%  
Dividend payout %18.70-   
Avg Mkt Cap Rs m3,9587,074 55.9%   
No. of employees `000NA2.8 0.0%   
Total wages/salary Rs m2,1641,449 149.3%   
Avg. sales/employee Rs ThNM1,874.1-  
Avg. wages/employee Rs ThNM527.0-  
Avg. net profit/employee Rs ThNM-407.7-  
INCOME DATA
Net Sales Rs m12,1275,154 235.3%  
Other income Rs m229100 229.8%   
Total revenues Rs m12,3565,254 235.2%   
Gross profit Rs m1,009-766 -131.7%  
Depreciation Rs m594711 83.5%   
Interest Rs m4151,503 27.6%   
Profit before tax Rs m230-2,881 -8.0%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m0-6 5.3%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m-7317 -432.9%   
Profit after tax Rs m302-1,121 -26.9%  
Gross profit margin %8.3-14.9 -56.0%  
Effective tax rate %-31.7-0.6 5,428.1%   
Net profit margin %2.5-21.8 -11.5%  
BALANCE SHEET DATA
Current assets Rs m6,8843,810 180.7%   
Current liabilities Rs m8,4568,365 101.1%   
Net working cap to sales %-13.0-88.4 14.7%  
Current ratio x0.80.5 178.7%  
Inventory Days Days62156 39.6%  
Debtors Days Days10867 160.0%  
Net fixed assets Rs m4,97014,480 34.3%   
Share capital Rs m11361 184.8%   
"Free" reserves Rs m2,875903 318.3%   
Net worth Rs m3,0205,127 58.9%   
Long term debt Rs m1,8175,832 31.2%   
Total assets Rs m13,34719,433 68.7%  
Interest coverage x1.6-0.9 -169.5%   
Debt to equity ratio x0.61.1 52.9%  
Sales to assets ratio x0.90.3 342.6%   
Return on assets %5.42.0 273.6%  
Return on equity %10.0-21.9 -45.7%  
Return on capital %13.33.6 366.4%  
Exports to sales %46.424.5 189.0%   
Imports to sales %14.210.2 139.9%   
Exports (fob) Rs m5,6221,264 444.8%   
Imports (cif) Rs m1,728525 329.2%   
Fx inflow Rs m5,8431,539 379.6%   
Fx outflow Rs m2,173942 230.7%   
Net fx Rs m3,669597 614.4%   
CASH FLOW
From Operations Rs m398599 66.4%  
From Investments Rs m-1,635-438 373.4%  
From Financial Activity Rs m1,309-303 -432.5%  
Net Cashflow Rs m71-141 -50.4%  

Share Holding

Indian Promoters % 39.2 74.5 52.6%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 3.6 0.6 600.0%  
FIIs % 17.6 1.3 1,353.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 23.6 167.8%  
Shareholders   20,750 10,259 202.3%  
Pledged promoter(s) holding % 12.3 35.1 35.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   WYETH LTD  PIRAMAL ENTERPRISES  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex, Nifty at Record Close Yet Again; IT & Realty Stocks Rally(Closing)

Indian share markets extended rally in the final hour of the trade, hitting fresh record highs while the Bank nifty touched 27,000 level for the first time. At the closing bell.

Related Views on News

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Dr Reddy's: No Respite from Pricing Pressure in the US (Quarterly Results Update - Detailed)

Nov 13, 2017

Pricing pressure continued to haunt Dr Reddy's although there was a significant improvement in its businesses sequentially.

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Glenmark: Most Geographies Show Weak Growth (Quarterly Results Update - Detailed)

Nov 7, 2017

Poor show in the US, Latam and India hit profits during the quarter.

More Views on News

Most Popular

Retail Investors or Chickens Waiting to Get Slaughtered in the Stock Market?(Vivek Kaul's Diary)

Jan 9, 2018

The price to earnings ratio of the Nifty 50 is very close to all-time high levels.

Best ELSS Funds In 2018: Don't Blindly Chase Top Performers(Outside View)

Jan 10, 2018

As the tax-saving season begins, investors hunt for the best ELSS funds for 2018. PersonalFN provides a list of the top ELSS mutual funds of the past year.

Did GST and Notebandi Help? Sherlock Holmes Finds Out...(The 5 Minute Wrapup)

Jan 13, 2018

Discussions with my cousin helped me understand the situation on Ground Zero - after the demonetization and GST upheaval. Here's what that means for listed companies...

Bitcoin Beginners Should Do These Three Things...(Smart Contrarian)

Jan 10, 2018

Three simple points to keep in mind before you consider buying bitcoin.

Nirvana denied: Has Value Failed?(The Honest Truth)

Jan 13, 2018

Should investors choose growth over value this year?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 5-YR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS